Dr. Reddy's Announces the Launch of Repatha in India

Dr. Reddy’s Laboratories Ltd. has launched Repatha (evolocumab) 140 mg/ml, the first and only PCSK9 Inhibitor available in India, approved by the Drug Controller General India (DCGI). The drug is a patented product of Amgen, and will be distributed in India by Dr. Reddy’s and manufactured by Amgen.

PCSK9 Inhibitors are a new class of lipid lowering drugs. They target and inactivate a specific protein in the liver called proprotein convertase subtilisin kexin 9. This leads to dramatic reduction in the amount of harmful LDL cholesterol circulating in the bloodstream.

Repatha is indicated for the treatment of adult patients with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia. It is used as an adjunct to diet in combination with a statin or statin with other lipid lowering therapies in patients who are unable to reach LDL-C goals with the maximum tolerated dose of a statin. It is used either alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. Repatha is also indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies.

According to Mr. M.V. Ramana, CEO, Branded Markets (India and Emerging Markets), the launch of Repatha is another significant addition to Dr. Reddy’s cardiovascular portfolio, providing “a unique treatment option to patients in India who are at risk of heart attack, stroke and coronary problems.”